Law360 (March 22, 2021, 9:44 PM EDT) — The U.S. Food and Drug Administration sent warning letters to a pair of companies that sell pain relief products containing CBD on Monday, suggesting the regulator will take action against CBD products that raise claims about even generic health benefits.
The letters, which went to Michigan-based BioLyte Laboratories LLC and California-based Honest Globe Inc., warned about marketing CBD products as unapproved new drugs, noncompliant manufacturing processes and more.
BioLyte and Honest Globe are not the first companies to be warned about CBD products by the FDA, but they stand out because the agency’s prior letters have largely gone to companies that…
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!
TRY LAW360 FREE FOR SEVEN DAYS